Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase II Study in Ulcerative Colitis

Prometheus Biosciences, Inc. announced the completion of enrollment for Cohort 1 of the ARTEMIS-UC global Phase II study of PRA023 in ulcerative colitis.